Gefitinib can improve survival in patients with esophageal cancer

Recently, the National Cancer Institute Cancer (NCRI) conference, researchers from the University of Aberdeen, said through research, the latest drug for treatment of lung cancer can make special esophageal cancer patient survival was significantly prolonged. Patients with esophageal body up to sixth in the tumor cells are able to find copies of EGFR, and patients often by taking drugs gefitinib to targeting the "wrong", and then the patient life expectancy can be extended to six months, sometimes even longer.

Antineoplastic Gefitinib is an epidermal growth factor receptor inhibitors, which has been approved in Japan, the US and Australia and many other countries for the treatment of advanced non-small cell lung cancer; esophageal cancer as the most common of the six one of malignant disease, its cause no obvious early symptoms often makes specific clinical diagnosis in most patients found to have advanced, only about 10% 5-year survival rate.

This study used therapies for the treatment of malignant esophageal first chemotherapy failed, and Human TSH ELISA Kit http://www.cusabio.com/cusabio-110365/ can effectively improve the survival of patients; while it is also an effective treatment for targeted therapies for other diseases; researchers in this study the test is named "TRANS-COG", researchers from 295 deceased patients with esophageal cancer in tumor samples organism extra copies of EGFR gene finding in the trial; 48 additional copies of the EGFR patients the body's tumor cells, accept gefitinib-treated patients, 13% of individuals have survived for at least a year, while placebo-treated individual survival time is not long.

The use of gefitinib treatment of patients do not carry the extra EGFR no obvious improvement in their survival, which shows, EGFR detection can identify acceptable gefitinib therapy to benefit patients with esophageal cancer; Dr. Russell Petty said this study, we first found gefitinib to effectively unresponsive to chemotherapy prolonged survival of patients with esophageal cancer, until now we therapy in the treatment of esophageal very limited, and the disease caused at least 8,000 deaths per year, while let's sad to late diagnosis of the patient tends to reduce the success of their treatment.

Researchers believe there are 16 percent of esophageal cancer patients will benefit because of gefitinib imatinib, finally, Professor Matt Seymour said that despite the improvement of gefitinib on survival in patients with relatively modest, but this study is to develop a new type of cancer treatment special therapy has taken an important step; scientists in the development of specific treatment of digestive cancer therapy has made certain achievements, but still difficult to deal with esophageal cancer, only 13% of the survival of patients greater than or equal to 5 years, if the drug gefitinib accurate targeting in patients with esophageal cancer, then it will be a very promising drug.